Malignant Large Intestinal Neoplasm

subtype

Identifier: CI-CAN-00003173
Entity page: /cancer/malignant-large-intestinal-neoplasm ↗
Edges: 8,320

Neighbours: 15 genes22 drugs10 trials
Drawn: 47 of 47 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Malignant Large Intestinal Neoplasm approved for …APPROVED_FORderived15 of 39show all (up to 200)
← approved for	Fluorouracilsmall molecule FDA (US) · approved · 2026-02-20 · FAVLYXA is a nucleoside metabolic inhibitor indicated for the treatment of patients with: Adenocarcinoma of the Colon and Rectum	—	approved	Colon Adenocarcinoma	1	Regulatory	openfda	graph →
approved for

Malignant Large Intestinal Neoplasm altered in cohorts of …ALTERED_INderived15 of 529show all (up to 200)
← altered in cohorts of	CD40 151 / 171 cases (88 %) · ssm · TCGA-READ	—	—	Rectal Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	HNF4A 150 / 171 cases (88 %) · ssm · TCGA-READ	—	—	Rectal Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PCK1 150 / 171 cases (88 %) · ssm · TCGA-READ	—	—	Rectal Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	RIMS4 150 / 171 cases (88 %) · ssm · TCGA-READ	—	—	Rectal Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	SGK2 150 / 171 cases (88 %) · ssm · TCGA-READ	—	—	Rectal Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	TRPC4AP 150 / 171 cases (88 %) · ssm · TCGA-READ	—	—	Rectal Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	BLCAP 149 / 171 cases (87 %) · ssm · TCGA-READ	—	—	Rectal Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	BMP7 149 / 171 cases (87 %) · ssm · TCGA-READ	—	—	Rectal Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	BPI 149 / 171 cases (87 %) · ssm · TCGA-READ	—	—	Rectal Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	BPIFB3 149 / 171 cases (87 %) · ssm · TCGA-READ	—	—	Rectal Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	COX4I2 149 / 171 cases (87 %) · ssm · TCGA-READ	—	—	Rectal Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	EDN3 149 / 171 cases (87 %) · ssm · TCGA-READ	—	—	Rectal Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	EMILIN3 149 / 171 cases (87 %) · ssm · TCGA-READ	—	—	Rectal Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	FAM83D 149 / 171 cases (87 %) · ssm · TCGA-READ	—	—	Rectal Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	FOXS1 149 / 171 cases (87 %) · ssm · TCGA-READ	—	—	Rectal Adenocarcinoma	1	Observed	gdc	graph →

Malignant Large Intestinal Neoplasm altered in cohorts of …ALTERED_INderived15 of 529show all (up to 200)

← altered in cohorts of

CD40

151 / 171 cases (88 %) · ssm · TCGA-READ

—

Rectal Adenocarcinoma

Observed

Malignant Large Intestinal Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 252show all (up to 200)
→ investigated in trials for	Fluorouracilsmall molecule 447 trials (77 active) · roll-up of the cancer and its descendants	—	—	Malignant Large Intestinal Neoplasm	447	Observed	clinicaltrials	graph →
→ investigated in trials for	Oxaliplatinsmall molecule 429 trials (109 active) · roll-up of the cancer and its descendants	—	—	Malignant Large Intestinal Neoplasm	429	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 384 trials (106 active) · roll-up of the cancer and its descendants	—	—	Malignant Large Intestinal Neoplasm	384	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall molecule 359 trials (99 active) · roll-up of the cancer and its descendants	—	—	Malignant Large Intestinal Neoplasm	359	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 337 trials (50 active) · roll-up of the cancer and its descendants	—	—	Malignant Large Intestinal Neoplasm	337	Observed	clinicaltrials	graph →
→ investigated in trials for	Leucovorinsmall molecule 302 trials (41 active) · roll-up of the cancer and its descendants	—	—	Malignant Large Intestinal Neoplasm	302	Observed	clinicaltrials	graph →
→ investigated in trials for	Cetuximabmonoclonal antibody 276 trials (61 active) · roll-up of the cancer and its descendants	—	—	Malignant Large Intestinal Neoplasm	276	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 119 trials (56 active) · roll-up of the cancer and its descendants	—	—	Malignant Large Intestinal Neoplasm	119	Observed	clinicaltrials	graph →
→ investigated in trials for	Panitumumabmonoclonal antibody 99 trials (20 active) · roll-up of the cancer and its descendants	—	—	Malignant Large Intestinal Neoplasm	99	Observed	clinicaltrials	graph →
→ investigated in trials for	FOLFOX Regimen 97 trials (30 active) · roll-up of the cancer and its descendants	—	—	Malignant Large Intestinal Neoplasm	97	Observed	clinicaltrials	graph →
→ investigated in trials for	FOLFIRI Regimen 91 trials (17 active) · roll-up of the cancer and its descendants	—	—	Malignant Large Intestinal Neoplasm	91	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 87 trials (40 active) · roll-up of the cancer and its descendants	—	—	Malignant Large Intestinal Neoplasm	87	Observed	clinicaltrials	graph →
→ investigated in trials for	Regorafenibsmall molecule 78 trials (17 active) · roll-up of the cancer and its descendants	—	—	Malignant Large Intestinal Neoplasm	78	Observed	clinicaltrials	graph →
→ investigated in trials for	Chemotherapy 69 trials (28 active) · roll-up of the cancer and its descendants	—	—	Malignant Large Intestinal Neoplasm	69	Observed	clinicaltrials	graph →
→ investigated in trials for	Fruquintinibsmall molecule 45 trials (23 active) · roll-up of the cancer and its descendants	—	—	Malignant Large Intestinal Neoplasm	45	Observed	clinicaltrials	graph →

Malignant Large Intestinal Neoplasm studied in …STUDIED_INderived10 of 7,500show all (up to 200)
→ studied in	NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 7,500 trials mapped (2,061 active)	—	—	Colon Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02980510Phase 2 · completed Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients · condition mapped CURATED_BROADER · 7,500 trials mapped (2,061 active)	—	—	Malignant Colorectal Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04751370Phase 2 · active not recruiting Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer · condition mapped CURATED_BROADER · 7,500 trials mapped (2,061 active)	—	—	Rectal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05322590Phase 1/Phase 2 · active not recruiting BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma · condition mapped CURATED_BROADER · 7,500 trials mapped (2,061 active)	—	—	Colorectal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05611034Phase 1 · recruiting In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung · condition mapped CURATED_BROADER · 7,500 trials mapped (2,061 active)	—	—	Malignant Colorectal Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05731271Phase 1/Phase 2 · active not recruiting A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors · condition mapped ONTOLOGY_EXACT · 7,500 trials mapped (2,061 active)	—	—	Colorectal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05803382Phase 1 · recruiting Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers · condition mapped CURATED_BROADER · 7,500 trials mapped (2,061 active)	—	—	Colorectal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05877599Phase 1 · recruiting A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation · condition mapped ONTOLOGY_EXACT · 7,500 trials mapped (2,061 active)	—	—	Colorectal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07127874Phase 1 · recruiting A Study of PHN-012 in Patients With Advanced Solid Tumors · condition mapped CURATED_EXACT · 7,500 trials mapped (2,061 active)	—	—	Malignant Colon Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07328516enrolling by invitation Natural History Study of Early Life Exposures in Agriculture (ELEA) · condition mapped CURATED_BROADER · 7,500 trials mapped (2,061 active)	—	—	Malignant Colorectal Neoplasm	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains